{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:06:36Z","timestamp":1790643996934,"version":"4.1.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2013,7,4]],"date-time":"2013-07-04T00:00:00Z","timestamp":1372896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,7,4]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>A retrospective chart review was conducted at a single centre, capturing data on 173 primary immunodeficiency disease (PIDD) patients, including 40 obese patients, using subcutaneous administration of immunoglobulin (Ig) (SCIG) (16 or 20%) delivered by infusion pump or subcutaneous (s.c.) rapid push. Patients previously using Ig administered as intravenous (i.v.) infusions (IVIG) were converted to SCIG dosing on a 1:1 basis. In both obese and non-obese patients, mean serum Ig levels were higher during SCIG administration (steady state) compared with IVIG administration (trough values). Similar SCIG dose\u2009:\u2009serum IgG level relationships were observed between obese and non-obese patients, suggesting the consistent bioavailability of SCIG regardless of body mass index (BMI). The mean SCIG volume per dosing site and the mean number of dosing days per week were greater with s.c. rapid push compared with infusion pump in this cohort, but the mean number of sites per infusion session was lower with s.c. rapid push. Both methods were well tolerated. The use of 20 versus 16% SCIG in obese patients improved dosing efficiency, resulting in smaller weekly volumes (54\u00b77 versus 74\u00b75\u2009ml\/week) and dosing on fewer days per week (2\u00b73 versus 3\u00b74 days). These data do not suggest a need for SCIG dosing adjustments in obese individuals relative to non-obese patients. The administration of SCIG using either infusion pump or s.c. rapid push is a practical and well-tolerated alternative to IVIG in obese patients. Offering various administration techniques provides a greater opportunity for treatment satisfaction and patient empowerment, which may support high levels of patient compliance.<\/jats:p>","DOI":"10.1111\/cei.12099","type":"journal-article","created":{"date-parts":[[2013,3,7]],"date-time":"2013-03-07T07:44:19Z","timestamp":1362642259000},"page":"365-371","source":"Crossref","is-referenced-by-count":31,"title":["Subcutaneous immunoglobulin (16 or 20%) therapy in obese patients with primary immunodeficiency: a retrospective analysis of administration by infusion pump or subcutaneous rapid push"],"prefix":"10.1093","volume":"173","author":[{"given":"R","family":"Shapiro","sequence":"first","affiliation":[{"name":"Midwest Immunology Clinic, Plymouth, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,7,4]]},"reference":[{"key":"2021122009571493800_cei12099-bib-0001","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.clim.2011.01.006","article-title":"Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies","volume":"139","author":"Berger","year":"2011","journal-title":"Clin Immunol"},{"key":"2021122009571493800_cei12099-bib-0002","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.iac.2008.07.002","article-title":"Subcutaneous administration of IgG","volume":"28","author":"Berger","year":"2008","journal-title":"Immunol Allergy Clin North Am"},{"key":"2021122009571493800_cei12099-bib-0003","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1023\/A:1006678312925","article-title":"The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy","volume":"20","author":"Chapel","year":"2000","journal-title":"J Clin Immunol"},{"key":"2021122009571493800_cei12099-bib-0004","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10875-006-9021-7","article-title":"Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases","volume":"26","author":"Ochs","year":"2006","journal-title":"J Clin Immunol"},{"key":"2021122009571493800_cei12099-bib-0005","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10875-006-9002-x","article-title":"Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies \u2013 a prospective, multi-national study","volume":"26","author":"Gardulf","year":"2006","journal-title":"J Clin Immunol"},{"key":"2021122009571493800_cei12099-bib-0006","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.iac.2008.06.006","article-title":"Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes","volume":"28","author":"Bonilla","year":"2008","journal-title":"Immunol Allergy Clin North Am"},{"key":"2021122009571493800_cei12099-bib-0007","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1097\/SMJ.0b013e3181eba6ea","article-title":"Improved quality of life, immunoglobulin G levels, and infection rate in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G","volume":"103","author":"Berger","year":"2010","journal-title":"South Med J"},{"key":"2021122009571493800_cei12099-bib-0008","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.jaci.2004.06.053","article-title":"Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home","volume":"114","author":"Gardulf","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"2021122009571493800_cei12099-bib-0009","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10875-006-8905-x","article-title":"Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home","volume":"26","author":"Nicolay","year":"2006","journal-title":"J Clin Immunol"},{"key":"2021122009571493800_cei12099-bib-0010","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10875-009-9352-2","article-title":"Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: a retrospective analysis","volume":"30","author":"Shapiro","year":"2010","journal-title":"J Clin Immunol"},{"key":"2021122009571493800_cei12099-bib-0011","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1001\/jama.2012.39","article-title":"Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999\u20132010","volume":"307","author":"Flegal","year":"2012","journal-title":"JAMA"},{"key":"2021122009571493800_cei12099-bib-0012","volume-title":"U.S. obesity trends","author":"Centers for Disease Control and Prevention","year":"2012"},{"key":"2021122009571493800_cei12099-bib-0013","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1001\/jama.2012.40","article-title":"Prevalence of obesity and trends in body mass index among US children and adolescents, 1999\u20132010","volume":"307","author":"Ogden","year":"2012","journal-title":"JAMA"},{"key":"2021122009571493800_cei12099-bib-0014","article-title":"Immunoglobulins and obesity: how do you dose intravenous immunoglobulin in morbidly obese patients?","volume-title":"Pharmacy Practice News","author":"Siegel","year":"2010"},{"key":"2021122009571493800_cei12099-bib-0015","year":"2010"},{"key":"2021122009571493800_cei12099-bib-0016","year":"2011"},{"key":"2021122009571493800_cei12099-bib-0017","volume-title":"Note for guidance on the clinical investigation of human normal immunoglobulin for subcutaneous and intramuscular use","author":"EMEA Committee for Proprietary Medicinal Products (CPMP)","year":"2002"},{"key":"2021122009571493800_cei12099-bib-0018","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.clim.2011.06.002","article-title":"Efficacy and safety of Hizentra(\u00ae) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy","volume":"141","author":"Jolles","year":"2011","journal-title":"Clin Immunol"},{"key":"2021122009571493800_cei12099-bib-0019","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1365-2249.2011.04376.x","article-title":"Efficacy and safety of home-based subcutaneous immunoglobulin replacement therapy in paediatric patients with primary immunodeficiencies","volume":"164","author":"Borte","year":"2011","journal-title":"Clin Exp Immunol"},{"key":"2021122009571493800_cei12099-bib-0020","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.clim.2011.02.020","article-title":"IgG replacement therapy, no size fits all","volume":"139","author":"Bonilla","year":"2011","journal-title":"Clin Immunol"},{"key":"2021122009571493800_cei12099-bib-0021","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.clim.2010.06.012","article-title":"Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies","volume":"37","author":"Orange","year":"2010","journal-title":"Clin Immunol"},{"key":"2021122009571493800_cei12099-bib-0022","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1365-2249.2012.04594.x","article-title":"Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy","volume":"169","author":"Orange","year":"2012","journal-title":"Clin Exp Immunol"},{"key":"2021122009571493800_cei12099-bib-0023","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jaci.2008.04.044","article-title":"Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection","volume":"122","author":"Bonagura","year":"2008","journal-title":"J Allergy Clin Immunol"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcei.12099","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/173\/2\/365\/41787771\/cei12099.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/173\/2\/365\/41787771\/cei12099.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T11:24:37Z","timestamp":1641036277000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/173\/2\/365\/6420971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,4]]},"references-count":23,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2013,7,4]]},"published-print":{"date-parts":[[2013,7,4]]}},"URL":"https:\/\/doi.org\/10.1111\/cei.12099","relation":{},"ISSN":["1365-2249","0009-9104"],"issn-type":[{"value":"1365-2249","type":"electronic"},{"value":"0009-9104","type":"print"}],"subject":[],"published-other":{"date-parts":[[2013,8]]},"published":{"date-parts":[[2013,7,4]]}}}